Clinical Trials Browser

Phase 1 × Autoimmune Diseases × Clear all

NCT03816345 2026-03-18

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT05451212 2025-11-10

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Phase 1 Completed

7 enrolled

Autoimmune Diseases, Immune System Diseases, Musculoskeletal Diseases, Myasthenia Gravis, Neuromuscular Diseases, Muscle Weakness

NCT06567080 2024-08-22

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

Phase 1 Not yet recruiting

15 enrolled

Autoimmune Diseases, Lupus Erythematosus, Systemic

NCT03656627 2023-02-15

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Phase 1 Terminated

7 enrolled

Thoracic

Arthritis, Rheumatoid, Autoimmune Diseases, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease, Lupus Erythematosus, Systemic, Multiple Sclerosis, Polymyalgia Rheumatica, Psoriasis, Giant Cell Arteritis

NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

Phase 1 Completed

25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms